RIPK1 and Alzheimer disease: For example, DNL747, a small-molecular inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1)—a kinase enzyme involved in the downstream signaling of the TNF-α receptor, is currently under phase I clinical trial investigation for its efficacy in modulating microglial activation and related neuroinflammation in patients with AD.163